RALEIGH, N.C., Aug. 17, 2017 /PRNewswire/ -- BioDelivery
Sciences International, Inc. (NASDAQ: BDSI) will present three
posters reviewing the potential impacts of BELBUCA®
(buprenorphine) buccal film (CIII) and BUNAVAIL®
(buprenorphine and naloxone) buccal film (CIII) on important issues
pertinent to the opioid epidemic, such as safety and diversion, at
the PAINWeek 2017 meeting in Las Vegas,
NV on September 5 - 9,
2017.
The posters are as follows:
- Poster #107: Respiratory Effects of the Treatment of Chronic
Pain with Buprenorphine when Administered as
BELBUCA®
- Poster #72: Potential Health Economic Benefits of
Buprenorphine Buccal Film in the Management of Chronic Pain
Patients
- Poster #86: Reduced Buprenorphine/Naloxone Prescriptions in
a State Medicaid Population Following Formulary Conversion from
Suboxone to BUNAVAIL®: Implications for Potential
Diversion
Further details on these PAINWeek 2017 poster presentations will
be provided in upcoming Company communications.
PAINWeek is the largest U.S. pain conference for frontline
clinicians with an interest in pain management. The annual
conference presents 120+ hours of continuing medical education
courses and master classes, special interest sessions, and
satellite events geared toward physicians, physician assistants,
nurse practitioners, nurses, pharmacists, hospitalists,
psychologists, and other healthcare professionals involved in pain
management.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a
specialty pharmaceutical company with a focus in the areas of pain
management and addiction medicine. BDSI is utilizing its
novel and proprietary BioErodible MucoAdhesive (BEMA®)
technology and other drug delivery technologies to develop and
commercialize, either on its own or in partnership with third
parties, new applications of proven therapies aimed at addressing
important unmet medical needs.
BDSI's marketed products and those in development address
serious and debilitating conditions such as breakthrough cancer
pain, chronic pain and opioid dependence. BDSI's headquarters
is in Raleigh, North Carolina.
For more information, please visit or follow us:
Internet:
|
www.bdsi.com
|
Facebook:
|
Facebook.com/BioDeliverySI
|
Twitter:
|
@BioDeliverySI
|
BUNAVAIL® (buprenorphine and naloxone) buccal film
(CIII) and BELBUCA® (buprenorphine) buccal film (CIII)
are marketed in the U.S. by BioDelivery Sciences.
ONSOLIS® (fentanyl buccal soluble film) (CII) is
licensed in the U.S. to Collegium Pharmaceutical pursuant to the
U.S. licensing and development agreement between BDSI and
Collegium. For full prescribing information and important safety
information on BDSI products, including BOXED WARNINGS for ONSOLIS,
please visit www.bdsi.com where the Company promptly
posts press releases, SEC filings and other important information
or contact the Company at (800) 469-0261. For full
prescribing and safety information on BELBUCA, please visit
www.belbuca.com and for full prescribing and safety
information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release and any statements of employees,
representatives and partners of BioDelivery Sciences International,
Inc. (the "Company") related thereto contain, or may contain, among
other things, certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve significant
risks and uncertainties. Such statements may include, without
limitation, statements with respect to the Company's plans,
objectives, projections, expectations and intentions and other
statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar
expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results (including, without limitation,
the Company's financial results and the impact of the Company's
products on the overall opioid market) may differ significantly
from those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS®,
BUNAVAIL® and BELBUCA® are registered
trademarks of BioDelivery Sciences International, Inc. The
BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks
owned by BioDelivery Sciences International, Inc. All other
trademarks and tradenames are owned by their respective owners.
© 2017 BioDelivery Sciences International, Inc. All rights
reserved.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biodelivery-sciences-to-present-three-posters-on-belbuca-and-bunavail-at-painweek-2017-300505713.html
SOURCE BioDelivery Sciences International, Inc.